Australia markets closed

Sangamo Therapeutics, Inc. (0R1D.L)

LSE - LSE Delayed price. Currency in USD
Add to watchlist
0.6427+0.0154 (+2.45%)
At close: 06:48PM GMT

Sangamo Therapeutics, Inc.

501 Canal Blvd
Richmond, CA 94804
United States
510-970-6000
https://www.sangamo.com

Sector(s)
Industry
Full-time employees405

Key executives

NameTitlePayExercisedYear born
Dr. Alexander D. Macrae Ch.B, M.B., MRCP, Ph.D.CEO, President & Director1.17MN/A1963
Ms. Prathyusha Duraibabu CPA, M.B.A.Senior VP, CFO & Principal Accounting Officer628.08kN/A1980
Ms. Amy Pooler Ph.D.Head of ResearchN/AN/AN/A
Mr. Gregory Davis Ph.D.Head of TechnologyN/AN/AN/A
Ms. Aron FeingoldHead of Corporate Communications & Investor Relations OfficerN/AN/AN/A
Mr. Scott B. WilloughbySenior VP, General Counsel & Corporate SecretaryN/AN/A1975
Dr. Nathalie Dubois-Stringfellow Ph.D.Senior VP & Chief Development OfficerN/AN/A1962
Phillip RamseyHead of Technical OperationsN/AN/AN/A
Ms. Stephanie J. Seiler CLPHead of Business Development & Alliance ManagementN/AN/AN/A
Mr. David OjalaScientist II - Discovery & Translational ResearchN/AN/AN/A
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease. Its preclinical development products focus on CAR-Treg cell therapies for autoimmune disorders and genome engineering for neurological diseases. Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Richmond, California.

Corporate governance

Sangamo Therapeutics, Inc.’s ISS governance QualityScore as of 1 March 2024 is 4. The pillar scores are Audit: 6; Board: 3; Shareholder rights: 2; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.